Hengrui Medicine receives FDA orphan drug designation for gastric cancer

Jiangsu Hengrui Medicine's combination therapy of anti-HER2 monoclonal antibody with camrelizumab and chemotherapy received U.S. FDA orphan drug designation for gastric and gastroesophageal junction adenocarcinoma.

The designation provides tax credits for clinical trials, waived application fees, and seven years of market exclusivity upon approval. The company invested approximately 1.26bn yuan developing the therapy.